Free Trial
NASDAQ:PROK

ProKidney Q3 2024 Earnings Report

ProKidney logo
$0.69 -0.06 (-8.40%)
Closing price 04:00 PM Eastern
Extended Trading
$0.69 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.14
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

ProKidney's Q1 2025 earnings is scheduled for Friday, May 9, 2025

ProKidney Earnings Headlines

ProKidney Corp.
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
ProKidney reports FY24 EPS (62c), consensus (59c)
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

View ProKidney Profile

More Earnings Resources from MarketBeat